companydata.dkcompanydata.dk

Y-mAbs Therapeutics A/S: Financial statements 2024

CVR: 37053678

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 74,262,634 and a net result of DKK -12,500,464 compared with DKK -27,748,840 the year before. That is an increase of 5.1% compared with the year before. Equity in the 2024 report amounted to DKK -125,190,245. The company had 56 employees in the financial year.

Gross Profit
DKK 74,262,634
Profit/Loss
DKK -12,500,464
Equity
DKK -125,190,245
Total Assets
DKK 26,470,481
Employees
56

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024-74.3M-12.5M-125.2M56
2023-70.7M-27.7M-112.7M59
2022-82.3M-85.7M-84.9M101
2021-67.5M-42.1M-39.3M88
2020-82.4M-1.2M2.8M62

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Thomas Gad joins the board of Y-mAbs Therapeutics A/SJul 31, 2024

As of July 31, 2024, Thomas Gad has joined the board of directors of Y-mAbs Therapeutics A/S.

Bo Kruse leaves the board of Y-mAbs Therapeutics A/SJul 31, 2024

As of July 31, 2024, Bo Kruse has left the board of directors of Y-mAbs Therapeutics A/S.

Thomas Gad leaves the board of Y-mAbs Therapeutics A/SJul 30, 2024

As of July 30, 2024, Thomas Gad has left the board of directors of Y-mAbs Therapeutics A/S.

Y-mAbs Therapeutics A/S: The 2023 annual report is outJun 29, 2024

Y-mAbs Therapeutics A/S has published its annual report for 2023. Gross profit came to DKK 70,656,043, and the net result was DKK -27,748,840.

About Y-mAbs Therapeutics A/S

Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.

Source: annual report 2025, Danish Business Authority